Abstract
Background:Despite the shared pattern of surface antigens, neoplastic cells in chronic lymphocytic leukemia (CLL) demonstrate heterogeneity in their molecular and functional characteristics. Given the dynamic variability of CD5 expression and its link to the proliferative pool of neoplastic cells, more detailed characterization of CLL cell subpopulations are needed.Aims:To further characterize the chemokine receptors (CCR5, CCR7, CCR10, CXCR3, CXCR4, CXCR5) and adhesion molecules (CD54, CD62L, CD49d) on the CD5high and CD5low neoplastic clones in peripheral blood in CLL.Methods:Study cohort consisted of CLL patients (n = 60) subgrouped according to the IgHV mutational status (IgHV mut, n = 24; IgHV unmut, n = 36). Chemokine receptors and adhesion molecules on CD5high and CD5low cell subpopulations, determined by CD5/CD19 co‐expression, in peripheral blood were assessed by a six‐colour flow cytometry analysis on a BD FACSCanto II (Becton Dickinson). Data were analysed by basic statistics and patient similarity networks.Results:CD5high cell subpopulation expressed high levels of CXCR3 (P < 0.001), CXCR5 (P = 0.005), CCR7 (P = 0.013), CCR10 (P = 0.001), CD62L (P = 0.031) compared to CD5low cells expressing high levels of CXCR4 (P < 0.001). When comparing IgHV mut from IgHV unmut patients, high‐levels of CXCR3 and CXCR5 on the whole neoplastic population as well as CD5high and CD5low subpopulations were detected in the IgHV mut patients. Multivariate patient similarity networks confirmed the significance of high CXCR3 levels predominantly on CD5low cells from IgHV mut patients.Summary/Conclusion:Our analysis revealed that CD5high and CD5low neoplastic clones from IgHV mut and IgHV unmut differed mainly by the expression of CXCR3. Further characterization of neoplastic cell heterogeneity and role of CXCR3 will advance our understanding of CLL biology and its clinical relevance.Grants: MZ ČR VES16‐32339A, IGA UP_2019_014, IGA_LF_2019_001, MH CZ–DRO (FNOL, 00098892)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
